Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 6/20 | 0.35 |
| ▸ | CA2 | P00918 | 6/20 | 0.35 |
| ▸ | CA9 | Q16790 | 6/20 | 0.35 |
| ▸ | LPL | P06858 | 2/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 7/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.34 |
| ▸ | F11 | P03951 | 2/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16021403 | 0.84 | LIPG (0.43) | ROCK1CA1CA2CA9LPL | |
| SCHEMBL16083230 | 0.84 | CA1 (0.35) | CA1CA2CA9LPLLIPG | |
| SCHEMBL16011263 | 0.79 | ROCK1 (0.44) | ROCK1CA1CA2CA9LPL | |
| SCHEMBL16021406 | 0.79 | ROCK1 (0.40) | ROCK1CA1CA2CA9LPL | |
| SCHEMBL2732475 | 0.78 | CA1 (0.38) | ROCK1CA1CA2CA9LPL | |
| SCHEMBL14488668 | 0.77 | ROCK1 (0.39) | ROCK1CA1CA2CA9LPL | |
| SCHEMBL2802131 | 0.77 | LPL (0.47) | ROCK1CA1CA2CA9LPL | |
| SCHEMBL13064191 | 0.77 | ROCK1 (0.40) | ROCK1CA1CA2CA9LPL | |
| SCHEMBL1791979 | 0.76 | LPL (0.46) | ROCK1CA1CA2CA9LPL | |
| SCHEMBL16896712 | 0.75 | CA1 (0.35) | ROCK1CA1CA2CA9LPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669296-B2 | LXR agonists and uses thereof | RGENIX, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| EP-2967073-B9 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-2967073-B9 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-2967073-B1 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2967073-B1 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | disclosed |
| US-9834542-B2 | LXR modulators | BRISTO-MYERS SQUIBB COMPANY (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834542-B2 | LXR modulators | BRISTO-MYERS SQUIBB COMPANY (US) | 2017-12-05 | — | — | US | disclosed |
| EP-2968275-B1 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-2968275-B1 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9751869-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-05 | — | — | US | disclosed |
| US-20140163081-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163081-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163081-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-8618154-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2435410-A2 | LXR MODULATORS | Exelixis Patent Company LLC (US) | 2012-04-04 | — | — | EP | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| WO-2010138598-A2 | LXR MODULATORS | EXELIXIS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138598-A2 | LXR MODULATORS | EXELIXIS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163081-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | ROCK1 2525/4885CA1 4488/4885CA2 4431/4885 |
| US-10669296-B2 | LXR agonists and uses thereof | NR1H3, NR1H2, NR1H4 | ROCK1 1228/4885CA1 4825/4885CA2 4713/4885 |
| US-20120071534-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | ROCK1 2525/4885CA1 4488/4885CA2 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.